NEEDHAM, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it will present new data at the 12th International Mesothelioma Interest Group (iMig) Conference being held October 22-24, 2014, in Cape Town, South Africa.
Investigators and members of the Verastem leadership team will give oral presentations discussing the Company’s development programs targeting cancer stem cells (CSC’s) with a focus on lead inhibitor VS-6063 (defactinib). VS-6063 targets CSC’s, a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy, and can mediate tumor recurrence both locally and at metastatic sites. VS-6063 targets CSC’s through the potent inhibition of focal adhesion kinase (FAK). Research on the FAK signaling pathway has revealed its critical role in CSC survival and disease progression.
Help employers find you! Check out all the jobs and post your resume.
